(Q36821981)

16 August 2017

1 reference

title

Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma (English)

1 reference

16 August 2017

1 reference

1 reference

Robert S Wallis

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

The journal of investigative dermatology. Symposium proceedings

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

16-21

1 reference

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Differential effects of TNF and LTalpha in the host defense against M. bovis BCG

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Depressed T‐Cell Interferon‐γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Novel human in vitro system for evaluating antimycobacterial vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

An ELISA for detection of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Reactivation of latent granulomatous infections by infliximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Identification by two-dimensional gel electrophoresis of a 58-kilodalton tumor necrosis factor-inducing protein of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650031

7 January 2021

10.1038/SJ.JIDSYMP.5650031

Identifiers

DOI

1 reference

16 August 2017

1 reference